Five things for pharma marketers to know: Wednesday, March 15, 2017

Share this content:


1. The FDA is considering creating an Office of Patient Affairs in an effort to coordinate patient engagement and provide a single point of entry for the patient community. (RAPS)

2. Alexion Pharmaceuticals plans to reduce its workforce by 7%. The restructuring comes roughly three months after CEO David Hallal and CFO Vikas Sinhathat resigned from the company. (GEN)

3. A FDA advisory committee voted 18-to-8, with one abstention, that the benefits of Endo Pharmaceuticals' painkiller Opana ER do not outweigh its risks. The vote came in the wake of outbreaks of HIV and hepatitis C related to abuse of the drug. (MedPage Today)

4. AstraZeneca's Lynparza reduced the risk of disease progression in patients with ovarian cancer in a clinical trial. The trial was aimed at getting approval for the drug as a second-line maintenance treatment. Lynparza is currently approved as a fourth-line treatment. (Reuters)

5. Several Republican lawmakers have said they oppose the American Health Care Act, the replacement legislation for the Affordable Care Act. (WaPo)

Share this content:
Scroll down to see the next article